IMRA - IMRA STOCK NEWS

Imara Inc. has commenced the Forte Phase 2b clinical trial of IMR-687 in patients with beta-thalassemia, marking a significant advancement in treatment options. This trial follows the initiation of the Ardent Phase 2b trial for sickle cell disease. The Forte trial aims to enroll about 120 adult patients, assessing the safety and effectiveness of IMR-687 in enhancing red blood cell maturation and reducing transfusion dependency. Beta-thalassemia affects approximately 288,000 individuals globally, underscoring the need for effective therapies.

BOSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA) announced its participation in key virtual investor conferences this September. CEO Rahul Ballal, Ph.D., will present at the Citi 15th Annual BioPharma Virtual Conference on September 9 and 10, discussing challenges in rare disease drug development and benign hematology. Additionally, he will engage in a virtual fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference on September 17. Live webcasts will be available on Imara's website.

Imara Inc. (Nasdaq: IMRA) has received Orphan Drug designation from the European Commission for IMR-687, aimed at treating sickle cell disease (SCD). This designation highlights the critical need for effective SCD treatments, as the condition significantly impacts patients' lives. The company is advancing IMR-687 through a Phase 2b clinical trial. Orphan Drug designation provides several advantages, including market exclusivity, reduced fees, and specialized regulatory support, facilitating the development and approval process for this therapy.

Imara Inc. (Nasdaq: IMRA) has commenced Phase 2b clinical trials of IMR-687 for sickle cell disease and beta-thalassemia, with the first patient dosed in its Ardent trial. The company presented positive interim results at the European Hematology Association Congress, indicating improved outcomes with IMR-687 treatment. FDA granted multiple designations for IMR-687, enhancing its market prospects. Financially, Imara reported a net loss of $10.2 million for Q2 2020, an increase from $5.4 million year-over-year, yet its cash position stands at $106.3 million, sufficient to support operations into mid-2022.

Imara Inc. (Nasdaq: IMRA) announced the dosing of the first patient in its Ardent Phase 2b clinical trial of IMR-687 for adult sickle cell disease (SCD) patients. The trial aims to evaluate higher doses of IMR-687, specifically 300 mg and potentially 400 mg, compared to a placebo, aiming for a significant increase in fetal hemoglobin (HbF) levels. Previous interim results from a Phase 2a trial indicated well-tolerated results, showing a statistically significant increase in F-cells. Top-line data from the Phase 2a trial is expected in Q4 2020.

Imara Inc. (Nasdaq: IMRA) will host a conference call and live webcast on August 14, 2020, at 8:30 a.m. ET to discuss Q2 2020 financial results and business updates. This clinical-stage biopharmaceutical company focuses on developing therapeutics for rare genetic disorders of hemoglobin. Its lead candidate, IMR-687, is a small molecule inhibitor designed for sickle cell disease and beta-thalassemia treatment. Investors can access the webcast on the Imara website, and further details are available through investor relations contacts.

IMARA (Nasdaq: IMRA) announced that the FDA has granted Fast Track and Rare Pediatric Disease designations for its drug IMR-687, aimed at treating beta-thalassemia. These designations facilitate expedited development and review processes. IMARA recently commenced a Phase 2b clinical trial for IMR-687 in adult patients and plans to initiate pediatric testing soon. Previously, IMR-687 received Orphan Drug designation for both beta-thalassemia and sickle cell disease. These advancements underline IMARA's commitment to develop effective treatments for rare genetic disorders.

Imara Inc. (Nasdaq: IMRA) announced its addition to the U.S. small-cap Russell 2000 Index, effective July 1, 2020, following its IPO in March. This inclusion is significant as approximately $9 trillion is benchmarked against Russell U.S. Indexes, enhancing the visibility and credibility of Imara in the investment community. The company is advancing IMR-687, a treatment for blood disorders, with expectations of continued growth. Imara aims to create value for patients and shareholders through its ongoing developments in innovative therapeutics.

IMARA Inc. (Nasdaq: IMRA) announced its 'Real Impact' initiative, providing grants to community organizations addressing the needs of patients with sickle cell disease (SCD) and beta-thalassemia. Originally planning to fund 20 grants, they increased the number to 25 due to heightened demand, especially for COVID-19 relief efforts. The company assessed grant applications based on community impact and execution plans. Nineteen grants will focus on COVID-19 relief, while others support social health and organizational enhancements.